REGULATORY

MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products

March 3, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s health ministry announced the new NHI prices to be applied under the FY2023 “off-year” drug price revision in the official gazette on March 3, with special raises for the price maintenance premium (PMP) to be applied to 143 products.…

To read the full story

Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023

REGULATORY

US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…